Neurocrine Biosciences (FRA:NB3) Other Current Liabilities: €322 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NB3 Neurocrine Biosciences Inc FRA:NB3
94 GF Score
Price €148.60
GF Value €164.56
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Neurocrine Biosciences Other Current Liabilities?

Neurocrine Biosciences FRA:NB3 -0.70% 94 Other Current Liabilities is €322 Mil as of Mar. 2026. GuruFocus rates FRA:NB3 with a GF Score™ of 94/100 and a GF Value™ of €164.56 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Neurocrine Biosciences's other current liabilities for the quarter that ended in Mar. 2026 was €322 Mil.

Neurocrine Biosciences's quarterly other current liabilities increased from Sep. 2025 (€338 Mil) to Dec. 2025 (€362 Mil) but then declined from Dec. 2025 (€362 Mil) to Mar. 2026 (€322 Mil).

Neurocrine Biosciences's annual other current liabilities increased from Dec. 2023 (€240 Mil) to Dec. 2024 (€284 Mil) and increased from Dec. 2024 (€284 Mil) to Dec. 2025 (€362 Mil).

Neurocrine Biosciences Other Current Liabilities Related Terms

Neurocrine Biosciences Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Neurocrine Biosciences's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences Other Current Liabilities Chart

Neurocrine Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 117.97 212.78 239.70 284.40 362.01

Neurocrine Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 240.32 274.84 337.99 362.01 321.52
FRA:NB3
94GF Score
Neurocrine Biosciences Inc FRA:NB3
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurocrine Biosciences Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €322 Mil mean?
Neurocrine Biosciences (FRA:NB3) has a Other Current Liabilities of €322 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Neurocrine Biosciences.
Is Neurocrine Biosciences' Other Current Liabilities too high?
Neurocrine Biosciences' current Other Current Liabilities is €322 Mil. Overall, Neurocrine Biosciences has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Other Current Liabilities compare to VTRS and ELAN?
Neurocrine Biosciences' Other Current Liabilities of €322 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Neurocrine Biosciences. Neurocrine Biosciences's current Other Current Liabilities is €322 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (FRA:NB3) is currently considered Modestly Undervalued. The stock's GF Value™ is €164.56, compared to a current price of €148.60 — trading 9.7% below its estimated fair value. The current Other Current Liabilities is €322 Mil. Neurocrine Biosciences' overall GF Score™ is 94/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Neurocrine Biosciences (FRA:NB3), the current Other Current Liabilities is €322 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neurocrine Biosciences (FRA:NB3) Overvalued in 2026?

Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued. The current stock price of €148.60 is trading 9.7% below its estimated GF Value™ of €164.56. GuruFocus considers Neurocrine Biosciences to be Modestly Undervalued.

Key valuation signals for FRA:NB3:

  • Other Current Liabilities: €322 Mil
  • GF Value™: €164.56 vs. price of €148.60 (9.7% below fair value)
  • GF Score™: 94/100 with 6 warning signs

No single metric tells the full story. See the FRA:NB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neurocrine Biosciences Business Description

Address 6027 Edgewood Bend Court, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
94GF Score

Get the complete analysis for FRA:NB3

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€148.60
Price
€164.56
GF Value